BACKGROUND: Overactive bladder(OAB) is characterized by symptoms of urgency, incontinence, frequency and nocturia. With the syndromic nature of the condition, clinical trials often solely report the most effective outcome i.e. the symptom with the largest improvement. As a result different interventions are evaluated for different outcomes, which can have severe implications for network meta-analyses, and consequently, decision-making. OBJECTIVES: To evaluate the use of multivariate network meta-analysis(MVNMA) to identify the most effective intervention for treating OAB syndrome.  METHODS: Using Bayesian Markov Chain Monte Carlo methods, we developed MVNMA accounting for the correlation between multiple outcomes to predict treatment effects for missing data. We extended this model to incorporate the exchangeability between treatment effects of the same intervention with different methods of administration (e.g. immediate release, extended release, intravesical etc.) and incorporated dose-response constraints on increasing doses. The outcomes of interest were mean change from baseline in incontinence, and urgency episodes. RESULTS: Independently, the datasets included 109 and 56 trials, evaluating 93 and 51 interventions, for incontinence and urgency episodes respectively. Sacral nerve stimulation appeared to be the most effective intervention for reducing incontinence with an estimated mean reduction of -8.9(95%CrI:-10.9,-7) episodes per 24hours relative to placebo. For urgency, sacral nerve stimulation was disconnected from the network and thus could not be not evaluated. Borrowing information between outcomes, the dataset for multivariate analyses included 117 trials evaluating all 95 treatments for OAB. Sacral nerve stimulation appeared to be the most effective intervention for both incontinence and urgency episodes with an estimated mean reduction of -8.3(95%CrI:-10.1,-6.9) and -9.1(95%CrI:-10.5,-7.3) episodes, respectively. CONCLUSIONS: Sacral nerve stimulation appeared to be the most effective intervention for treating OAB symptoms. MVNMA allowed us to evaluate all interventions across all outcomes, and in this case also increased precision in treatment effect estimates. Further work includes adjustment for baseline severity.